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Introduction
Caveolae are small plasma membrane invaginations in the sur-
face of many mammalian cell types. They are implicated in var-
ious physiological processes including endo- and transcytosis, 
pathogen entry, lipid regulation, signaling, and cancer (Razani 
et al., 2002; Parat, 2009). They can bud into the cell in the form 
of endocytic vesicles that dock onto endosomal organelles for 
cargo delivery (Pelkmans et al., 2004; Parton and Simons, 
2007). In the plasma membrane and during the vesicular trans-
port cycle, the caveolar coat remains tightly associated with the 
membrane, in striking contrast to other vesicle coats such as 
clathrin or COPI/II (Tagawa et al., 2005).
The caveolar coat is composed of two major layers of 
protein. The inner layer in nonmuscle cells is composed of 
CAV1  (caveolin-1)  and  CAV2.  The  caveolins  are  integral 
membrane proteins with a central hydrophobic domain in-
serted as a loop inside the membrane. With both N and C ter-
mini facing the cytoplasm, CAV1 assumes a hairpin topology 
(Dupree et al., 1993; Monier et al., 1995). With CAV1 as the 
major organizing subunit, the two caveolins form an inter-
connected scaffold that defines the size and many of the over-
all properties of the microdomain. The recently discovered 
cavins provide an outer peripheral cytosolic protein layer. 
They constitute large, heteroligomeric complexes that cover 
the highly curved membrane of plasma membrane caveolae 
(Bastiani et al., 2009; McMahon et al., 2009; Hayer et al., 
2010). They are thought to stabilize the caveolin scaffold, pro-
mote membrane curvature, and regulate budding of caveolae 
(Hill et al., 2008; Liu and Pilch, 2008; Bastiani et al., 2009; 
Hansen et al., 2009; McMahon et al., 2009). The lipid bilayer 
associated with caveolae represents a specialized microdomain 
enriched in cholesterol and sphingolipids.
Caveolins are synthesized in the ER, where they rapidly 
form SDS-resistant 8S oligomers containing 7–10 CAV1 and 
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aveolae are long-lived plasma membrane micro-
domains composed of caveolins, cavins, and a 
cholesterol-rich membrane. Little is known about 
how caveolae disassemble and how their coat compo-
nents  are  degraded.  We  studied  the  degradation  of   
caveolin-1 (CAV1), a major caveolar protein, in CV1 cells. 
CAV1 was degraded very slowly, but turnover could be 
accelerated by compromising caveolae assembly. Now, 
CAV1 became detectable in late endosomes (LE) and lyso-
somes where it was degraded. Targeting to the degrada-
tive pathway required ubiquitination and the endosomal 
sorting complex required for transport (ESCRT) machin-
ery for inclusion into intralumenal vesicles in endosomes. 
A dual-tag strategy allowed us to monitor exposure of 
CAV1 to the acidic lumen of individual, maturing LE in 
living cells. Importantly, we found that “caveosomes,” 
previously described by our group as independent or-
ganelles distinct from endosomes, actually correspond to 
late endosomal compartments modified by the accumula-
tion of overexpressed CAV1 awaiting degradation. The 
findings led us to a revised model for endocytic trafficking 
of CAV1.
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To lower the level of cholesterol in the plasma membrane 
and  the  Golgi  complex,  we  used  U18666A,  an  amphiphilic 
amine that inhibits cholesterol synthesis and perturbs choles-
terol trafficking. It induces cholesterol accumulation in swollen 
LE/LYS, thereby depleting cholesterol elsewhere (Cubells et al., 
2007). The CAV1-mEGFP in the plasma membrane of U18666A-
treated CV1 cells was predominantly uniformly distributed with 
only few defined spots characteristic of caveolae (Fig. 1 B). 
Consistent with the lack of caveolae, FRAP analysis showed 
that the CAV1-mEGFP in the plasma membrane was signifi-
cantly more mobile than in untreated cells (Fig. 1 C). Under 
normal conditions, caveolae are stable and immobile unless ac-
tivated (Thomsen et al., 2002; Tagawa et al., 2005).
Did the unassembled CAV1 originate from plasma mem-
brane caveolae or from a defect in caveolae assembly? We under-
took total internal reflection (TIR) fluorescence microscopy 
(TIR-FM) in live cells to discriminate between these possibilities. 
In control cells, caveolar scaffolds arrive at the plasma membrane 
from the Golgi in preassembled form in vesicular carriers distinct 
from those used by most other membrane cargo (Tagawa et al., 
2005; Hayer et al., 2010). When vesicles fuse with the plasma 
membrane, the CAV1 does not diffuse away but persists as im-
mobile, tight spots. That the CAV1-mEGFP transport was differ-
ent in CV1 cells pretreated with U18666A was shown by two 
observations. First, the CAV1-mEGFP was delivered to the cell 
surface in tubular rather than small vesicular carriers (Fig. 1 D and 
Video 1; Tagawa et al., 2005). Such tubular carriers are typical of 
the constitutive pathway of transport from the Golgi to the plasma 
membrane (Toomre et al., 1999). Second, the CAV1-mEGFP rap-
idly dispersed from the site of vesicle fusion laterally into the sur-
rounding plasma membrane (Fig. 1 D and Video 1). This suggested 
that it arrived in unassembled or easily dissociated form. The 
most likely explanation for the diffuse plasma membrane staining 
was that by depleting cholesterol, the assembly of intact caveolin 
scaffolds was inhibited in the Golgi complex. Apparently, the un-
assembled or incompletely assembled CAV1 was transported to 
the surface via a constitutive vesicle transport pathway and not   
by the alternative pathway normally used by caveolar scaffolds 
(Hayer et al., 2010). Although it was not obvious in the TIR-FM 
videos, it was possible that disassembly of caveolae at the plasma 
membrane could contribute to the phenotype. We have previously 
shown loss of caveolar spots and a rise in diffuse CAV1 staining 
when cholesterol is removed from the plasma membrane using 
methyl--cyclodextrin (Tagawa et al., 2005).
In addition to the diffuse plasma membrane staining of 
CAV1 in U18666A-treated cells, CAV1 was found in some of 
the large, swollen cytoplasmic organelles that the inhibitor in-
duced in cells. Confocal microscopy showed that these were posi-
tive for the late endosomal/lysosomal marker Lamp1 (Fig. 1, 
E and F). They were scattered around the cytoplasm and had 
the appearance of caveosomes as described in CAV1-EGFP– 
expressing cells (Pelkmans et al., 2001).
The effects of CAV1 overexpression and 
cavin-1 silencing
Overexpression of CAV1-mEGFP induced by transient trans-
fection provided another perturbation with similar effects on 
CAV2 molecules (Scheiffele et al., 1998; Fernandez et al., 2002; 
Hayer  et  al.,  2010). After  COPII-dependent  transport  to  the 
Golgi complex, the 8S oligomers associate with cholesterol and 
with each other to form the aforementioned membrane-embedded 
scaffold composed of 15–25 8S complexes. The scaffolds sedi-
ment as 70S particles when extracted from the membrane and 
delipidated (Hayer et al., 2010). A special vesicular pathway is 
responsible for transporting the caveolin scaffolds to the plasma 
membrane, where the cavins associate with them in the form of 
large 60S complexes (Hayer et al., 2010).
Once properly formed, caveolae in the plasma membrane 
are stable structures in which neither the caveolins nor the cavins 
undergo rapid turnover. They can be activated and undergo   
endocytic internalization (Kirkham et al., 2005; Tagawa et al., 
2005), and there is evidence that they can participate in cycles of 
fusion and fission with the plasma membrane (Pelkmans and 
Zerial, 2005). Cholesterol is not only needed for assembly of 
caveolae but also for stability (Rothberg et al., 1992). Cavins 
also contribute to the stability of caveolae as down-regulation of 
cavin-1 shortens the half-life of CAV1 (Hill et al., 2008; Hansen 
et al., 2009). Because the degradation of CAV1 after cavin-1 
down-regulation is sensitive to lysosomal inhibitors, it is possi-
ble that it occurs in lysosomes (LYS; Hill et al., 2008). However, 
it has been reported that mutants of CAV1 that fail to assemble 
into caveolae and thus remain trapped in the Golgi, and CAV2 
expressed in the absence of CAV1, are degraded by a protea-
somal pathway (Galbiati et al., 2000; Razani et al., 2001).
In this study, we address the processes by which caveolae 
and CAV1 undergo assembly, disassembly, and especially deg-
radation. By altering the balance of the different components of 
caveolae in the cell (CAV1, cavin-1, and cholesterol), we could 
inhibit caveolae assembly, thereby accelerating CAV1 degrada-
tion. Thus, the unassembled CAV1 generated was targeted to 
endosomes, ubiquitinated, sequestered in intralumenal vesicles 
(ILV) by the endosomal sorting complex required for transport 
(ESCRT) machinery, and degraded in LYS. The vacuoles previ-
ously described as caveosomes could be identified as late endo-
somes (LE) and LYS (LE/LYS) enriched in CAV1 destined   
for degradation.
Results
Unassembled caveolin in the  
plasma membrane
To learn more about the life cycle of caveolae and about CAV1 
degradation, we analyzed the consequences of perturbing the ra-
tios and availability of caveolar components in CV1 cells. Manip-
ulation was performed in three ways, depleting cells of cholesterol, 
overexpressing CAV1, and knocking down cavin-1 expression.
Cholesterol depletion was performed in CV1 cells stably 
expressing CAV1–monomeric EGFP (mEGFP). This cell line 
produced CAV1-mEGFP homogenously at levels similar to that 
of  endogenous  CAV1,  resulting  in  moderate  overexpression 
(Fig. S1 A). By fluorescence microscopy, CAV1-mEGFP was 
observed as familiar, subresolution spots in the plasma mem-
brane corresponding to caveolae (Fig. 1 A) and as a diffuse stain-
ing of the Golgi complex.617 Caveolin degradation • Hayer et al.
Figure 1.  Unassembled caveolin in the plasma membrane. (A and B) CV1-CAV1-mEGFP cells were left untreated (A) or treated with 5 µg/ml U18666A for 
16 h (B), fixed, and viewed by confocal microscopy. U18666A treatment resulted in a noncaveolar pool of CAV1 in the plasma membrane. (right) Insets 
show enlargements of the boxed areas. (C) FRAP analysis of the noncaveolar surface pool of CAV1. 4 × 4–µm squares were photobleached in the periphery 
of either CV1-CAV1-mEGFP cells (5 µg/ml U18666A treated for 16 h [n = 10 cells]; and untreated [n = 5 cells]) or a CV1 cell line stably expressing GFP-GPI 
(n = 15 cells). Error bars indicate mean ± SEM. (D) CV1 cells pretreated with 5 µg/ml U18666A (16 h) were transfected with CAV1-mEGFP and post-Golgi 
trafficking imaged by TIR-FM time-lapse imaging (1 Hz). The evanescent field was adjusted such that the plasma membrane and part of the Golgi were illumi-
nated. Tubular carriers arriving at the surface and releasing CAV1-mEGFP upon fusion with the plasma membrane are seen. Note that CAV1-mEGFP diffused 
laterally, and no caveolar spots were left behind (see Video 1). (top) Insets show enlargements of the boxed area. (E–G) Treating CV1-CAV1-mEGFP cells with 
5 µg/ml U18666A (16 h) or overexpressing CAV1-mEGFP in CV1 cells (16 h) induced unassembled CAV1 in the plasma membrane and targeting of CAV1-
mEGFP to Lamp1-positive LE (single confocal sections). (bottom) Insets show enlargements of the corresponding boxed areas. Arrowheads point to Lamp1-
positive LE, indicating absence (E) or presence (F and G) of colocalization with CAV1-mEGFP. Bars: (B, D [bottom], and E–G) 10 µm; (D [top]) 2 µm.JCB • VOLUME 191 • NUMBER 3 • 2010   618
LysoTracker, a marker for LE/LYS (Fig. 2, B and C). Furthermore, 
sucrose  velocity  gradient  centrifugation  of  HeLa-CAV1-mRFP   
extracts showed that cavin-1 knockdown resulted in an almost 
complete loss of the 70S CAV1 complexes, which is consistent 
with the observed redistribution of CAV1-mRFP from a caveolar   
to a noncaveolar surface pool composed of 8S complexes   
(Fig. 2 A). Apparently, the CAV1 in the vacuoles was also present 
as 8S complexes. Because cavin-1 is not needed for assembly of 
the caveolin scaffold in the Golgi complex (Hayer et al., 2010), the 
effect of cavin-1 knockdown was most likely explained by instabil-
ity of assembled caveolar scaffolds in the absence of cavins.
Collectively, the results indicated that interfering with the 
assembly of caveolae resulted in the appearance of an unassem-
bled, rapidly diffusing pool of caveolins in the plasma mem-
brane, probably representing 8S complexes. Furthermore, CAV1 
accumulated in LE/LYS, where it was not detectable under nor-
mal conditions. Cholesterol depletion, CAV1 overexpression, and 
silencing of cavin-1 all had similar effects.
Acidification is required for  
CAV1 degradation
To determine the half-life of CAV1, we used metabolic labeling 
with [
35S]Cys/Met and a pulse-chase approach. The amount of 
labeled CAV1 was determined at different times of chase using 
immunoprecipitation with the anti-CAV1 (N20) antibody, SDS-
PAGE, and autoradiography. Under normal conditions, the endog-
enous CAV1 proved to be an extremely long-lived protein in 
CV1 and HeLa cells. The half-life was much longer than 36 h 
(Fig. 3 A and not depicted). This was consistent with the stability 
demonstrated for caveolar domains in the plasma membrane of 
cells (Thomsen et al., 2002; Tagawa et al., 2005). However, tran-
siently overexpressed CAV1-HA was degraded at a much higher 
rate, and we could estimate its half-life to 13.6 h (Fig. 3 A).
caveolae assembly and CAV1 distribution in the cell. When 
CAV1-mEGFP was transiently overexpressed and allowed to 
accumulate over 16 h in CV1 cells, the distribution of CAV1 
showed, in addition to a uniform fluorescence in the plasma 
membrane, accumulation of label in the Golgi complex and in 
Lamp1-positive LE/LYS (Fig. 1 G). Co-overexpression of cavin-1 
with CAV1 did not reverse this effect (Fig. S1 C).
It is important to note that a few hours after transfection 
with CAV1 constructs, most of the expressed CAV1 was already 
localized to the noncaveolar surface pool and to endosomal or-
ganelles; i.e., their localization differed from that observed for 
endogenous CAV1 in control cells. Transiently overexpressed 
CAV1 was therefore not a suitable marker for caveolae beyond 
a certain time of expression. The extent of mislocalization also 
depended on cell type and transfection method. For example, 
after transfection by electroporation or lipid-based transfection 
methods (see Materials and methods), expression for 4–5 h was 
enough to show mislocalization in CV1 cells. When expression 
of CAV1 constructs was necessary, as it was in the visualization 
of CAV1 in live cells, it was better to use cell lines stably ex-
pressing the CAV1 constructs. The expression level was lower, 
and the CAV1 distribution generally mirrored that observed for 
endogenous CAV1 in control cells.
The third manipulation of CAV1 assembly involved cavin-1, 
another essential caveolar coat component. Because knockdown of 
cavin-1 by siRNA causes concomitant down-regulation of endog-
enous CAV1 (Hill et al., 2008; Hansen et al., 2009; Hayer et al., 
2010), an siRNA that targeted cavin-1 was transfected into HeLa 
cells  stably  expressing  CAV1–monomeric  RFP  (mRFP;  HeLa-
CAV1-mRFP). This resulted in efficient knockdown of cavin-1 
with only partial loss of CAV1-mRFP expression (Fig. 2 A). 
CAV1-mRFP was now present as a uniform pool in the plasma 
membrane and in cytoplasmic vacuoles that could be stained with 
Figure 2.  Cavin-1 knockdown. (A) Cavin-1 knockdown in HeLa-CAV1-mRFP cells caused an almost complete redistribution of assembled 70S-CAV1 into 
unassembled 8S-CAV1 as determined by sucrose velocity gradient centrifugation. (B and C) HeLa-CAV1-mRFP cells treated with control siRNA (B) or siRNA 
targeting cavin-1 (C) were loaded with 100 nM LysoTracker (green) for 1 h and imaged live by confocal microscopy. Cavin-1 knockdown caused loss of 
caveolar spots in the plasma membrane and accumulation of CAV1-mRFP in acidic, LysoTracker-positive organelles. (B and C, bottom) Insets show enlarge-
ments of boxed areas. Blots and images are representative of at least three independent experiments. Bars, 10 µm.619 Caveolin degradation • Hayer et al.
Together, these data indicated that CAV1 was targeted to LYS for 
degradation. This also occurred in the stably expressing cells 
with a normal intracellular CAV1 distribution and only mildly 
overexpressing CAV1-mRFP (Fig. S1 B).
CAV1 in the endo/lysosomal pathway
When CAV1–monomeric Cherry (mCherry) was transiently co-
expressed in CV1 cells with EGFP-tagged Rab5, Rab7, or Lamp1, 
colocalization was observed in cytoplasmic vacuoles using con-
focal fluorescence microscopy in fixed and live cells (Fig. 4, A–C). 
We undertook quantitative colocalization analysis based on images 
acquired from live cells coexpressing CAV1-mCherry and a   
GFP-tagged endosomal marker. Altogether, 6 × 10
4 endosomes 
The shorter half-life of overexpressed CAV1-HA allowed 
us to study the pathway of degradation using inhibitors. The 
degradation of CAV1-HA was completely inhibited by bafilo-
mycin A1 (BafA) and NH4Cl, which inhibit lysosomal degrada-
tion by raising the lumenal pH (Fig. 3 B). The proteasomal 
inhibitor MG132 had a partial effect, which is consistent with 
an indirect role described for proteasomes in endosome matura-
tion and the lysosomal degradation of the EGF receptor (Longva 
et al., 2002). U18666A and leupeptin had little or no effect on 
degradation. Consistent with the inhibitor profile, HeLa cells 
stably expressing CAV1-mRFP and treated with BafA, NH4Cl, 
or MG132 showed increased accumulation of CAV1-mRFP   
in endosomal structures relative to control cells (Fig. 3 C).   
Figure 3.  CAV1 degradation requires endosomal acidification. (A) Degradation time course of endogenous CAV1 and transiently transfected CAV1-HA in 
CV1 cells as determined by a pulse-chase experiment (see Materials and methods). t1/2 of CAV1-HA was 13.6 h, as determined by an exponential fit to 
data points from n = 3 independent experiments. Endogenous CAV1 was degraded much slower (t1/2 >36 h). (B) Degradation of CAV1-HA was inhibited 
by 0.2 µM BafA and 20 mM NH4Cl, which neutralize endosomal acidification, and by 10 µM MG132, an inhibitor of the ubiquitin–proteasome system.   
Error bars indicate mean ± SEM (n = 3–5 independent experiments). (C) Treatment of HeLa-CAV1-mRFP cells with BafA, NH4Cl, or MG132 caused   
accumulation of CAV1-mRFP in endosomal organelles. Single confocal sections of living cells, focus set to perinuclear endosomes. Insets show enlargements 
of boxed areas. Bars, 10 µm.JCB • VOLUME 191 • NUMBER 3 • 2010   620
The pH ranges from 6.0 to 6.5 in EE and 5.5 in LE to 4.7 in   
LYS (Kielian and Cohn, 1982; Zen et al., 1992).
It has been shown that acidification of endosomes can be 
followed using protein cargo with a tandem tag that contains 
both EGFP and mCherry (Pankiv et al., 2007). EGFP fluores-
cence is quenched in LYS, whereas mCherry is not. Following 
a similar strategy, we coexpressed CAV1-mEGFP and CAV1-
mCherry in CV1 cells and performed live cell confocal imag-
ing. The caveolar spots in the plasma membrane and in the 
limiting membrane of endosomes were yellow, as expected of 
mixed fluorescence emitted by CAV1-mEGFP and -mCherry 
(Fig. 5 A, dashed inset). The diffuse staining of the plasma 
membrane representing free CAV1 was also yellow.
However, many cytoplasmic vacuoles had the bright red 
color of mCherry consistent with selective quenching of mEGFP 
(Pankiv et al., 2007). To test whether this was caused by low 
pH, cells expressing CAV1-mCherry were loaded with 100 nM 
LysoTracker green for 1 h and imaged live. Most if not all acidic 
organelles marked by LysoTracker were positive for CAV1-
mCherry (Fig. 5 B). When cells coexpressing CAV1-mCherry 
and CAV1-mEGFP were treated with 0.2 µM BafA (12 h) to 
neutralize the lumenal pH, the vacuoles were all fluorescent 
both in mCherry and mEGFP channels (Fig. 5 C). Similar   
results were obtained when 20 mM NH4Cl (12 h) was used   
instead of BafA (unpublished data).
Because  the  mEGFP  and  mCherry  were  tagged  to  the   
C terminus of CAV1, the topology dictated that they would be   
inside the ILV. The loss of green fluorescence must therefore have 
involved lysis of ILV and exposure of the interior of these vesi-
cles to low pH. To follow this process in individual endosomes, 
cells  coexpressing  CAV1-mEGFP  and  CAV1-mCherry  were 
imaged live for 45 min using an epifluorescence microscope. 
Numerous endosomes initially yellow were seen to lose their 
green mEGFP fluorescence over time, whereas the red mCherry 
fluorescence remained constant (Fig. 5 D–F; and Video 3). Im-
portantly, the loss of mEGFP fluorescence was not caused by 
photobleaching, as the overall perinuclear mEGFP fluorescence 
remained constant (Fig. 5 D). The use of CAV1 constructs thus 
provided a method to follow the late stages in the maturation of 
individual endosomes and multivesicular bodies in living cells.
Together, our data argued for a model in which CAV1 pres-
ent in endosomes was sequestered into ILV. As the endosomes 
matured and fused with LYS, it was exposed to the acidic lumen 
and eventually degraded. Overexpression of CAV1 and the lack of 
efficient caveolae assembly enhanced this process so that CAV1 
became an easily detected component in the lumen of LE/LYS.
CAV1 is ubiquitinated, and ubiquitination  
is required for degradation
Targeting of membrane proteins to ILV is usually controlled by the 
addition of ubiquitin groups to their cytosolic domain (Raiborg 
and Stenmark, 2009). To determine whether CAV1 was ubiqui-
tinated, HA-tagged CAV1 was expressed in HEK293 cells and 
immunoprecipitated from extracts using the anti-CAV1 (N20) anti-
body. Western blot analysis using anti-HA antibody revealed the 
presence of multiple slower migrating CAV1 species in addition 
to the major band of CAV1-HA (Fig. 6 A). Probing equivalent 
were analyzed from cells expressing CAV1-mCherry/EGFP- 
Rab5 (n = 68), CAV1-mCherry/EGFP-Rab7 (n = 68), and   
CAV1-mCherry/Lamp1-EGFP (n = 43). The results showed that of 
the CAV1-mCherry–positive endosomal structures, 27% colocal-
ized  with  EGFP-Rab5,  61%  with  EGFP-Rab7,  and  67%  with 
Lamp1-EGFP (Fig. 4 G and Fig. S2 A). In live cells, CAV1-
mCherry colocalized with EGFP-Rab5 in the limiting membrane 
of early endosomes (EE), whereas in LE/LYS positive for EGFP-
Rab7 or Lamp1-EGFP, it was mainly present in the lumen. There-
fore, LE/LYS appeared as red (CAV1-mCherry) spots with a green 
(EGFP-Rab7 and Lamp1-EGFP) boundary (Fig. 4 D). Because 
CAV1 is a membrane protein, it was most likely sequestered in the 
ILV that fill the lumen of LE/LYS. These results indicated that 
CAV1-mCherry did not only reach the early endosomal compart-
ments but continued into the degradative branch of the endocytic 
pathway with accumulation in ILV of LE/LYS.
Cavin-1 associates with fully assembled caveolar scaf-
folds in the plasma membrane but not with biosynthetic inter-
mediates or unassembled forms of CAV1 (Hill et al., 2008; 
Hayer et al., 2010). Therefore, we used cavin-1 as a sensor to 
assess the assembly state of CAV1 in the endosomal pathway. 
When coexpressed with EGFP-Rab5 and CAV1-HA, cavin-1–
mCherry was found to colocalize with CAV1 in EE, indicating 
that early endosomal CAV1 is, at least partly, still assembled in 
caveolar scaffolds (Fig. 4 E). Conversely, when coexpressed 
with EGFP-Rab7 and CAV1-HA, cavin-1–mCherry did not co-
localize with the late endosomal marker, most likely because 
CAV1  scaffolds  had  disassembled  before  reaching  LE/LYS 
(Fig. 4 F). Disassembly of caveolar scaffolds may therefore be 
linked to progression of CAV1 in the endolysosomal pathway.
Visualization of CAV1 in LE/LYS in fixed cells was found 
to be problematic because of poor fixation of these organelles in 
CV1 cells with various different formaldehyde (FA)-based fixa-
tives. This was most clearly observed when the process was fol-
lowed in the microscope; the majority of Lamp1-EGFP–positive 
LE/LYS lost CAV1-mCherry after addition of FA (Fig. S2 B and 
Video 2). The lumenal CAV1-mCherry was released into the sur-
rounding  cytoplasm,  leaving  an  empty  Lamp1-EGFP  labeled 
“ghost” behind. The limiting membranes of LE/LYS were appar-
ently fixed properly, but the content of many vacuoles was lost. 
As a consequence, we avoided fixation when visualizing late 
compartments of the endocytic pathway and used live cell micros-
copy with fluorescently labeled proteins and cargo instead.
CAV1 in the acidic lumen of LE/LYS
CAV1 is embedded in the cytoplasmic leaflet of membranes 
with both N and C termini facing the cytosol. To be degraded, it 
must be exposed to the hydrolases in the lumen of LE/LYS.   
In analogy to degradation of cell surface receptors, this could 
occur by inclusion into inward budding vesicles during ILV for-
mation followed by lysis or degradation of the ILV in LYS.
To test whether CAV1 was exposed to the acidic lumen of 
LE/LYS, we took advantage of the difference in pH sensitivity 
of mCherry and EGFP fluorescence. Although EGFP fluorescence 
is quenched at pH values <6 (pKa 6.0), mCherry remains brightly 
fluorescent in acidic environments down to pH 4.5 (pKa <4.5; 
Kneen et al., 1998; Shaner et al., 2004; Shaner et al., 2005). 621 Caveolin degradation • Hayer et al.
Figure 4.  CAV1 and cavin-1 in the endosomal pathway. (A–C) CAV1-mCherry localized to Rab5-positive EE and to Rab7- and Lamp1-positive LE/LYS. 
Single confocal sections of fixed (A) or living (B and C) cells were acquired 12 h after transfection. (bottom) Insets show enlargements of boxed areas.   
(D) Enlarged views of individual organelles. In EE, CAV1-mCherry was present in the limiting membranes and, in LE/LYS, in the lumen of the organelles.   
(E and F) Cavin-1–mCherry localized to Rab5-positive EE but not to Rab7-positive LE. Cavin-1–mCherry was coexpressed with GFP-tagged endosomal makers 
and CAV1-HA (not depicted), and images acquired 12 h after transfection form living cells using an epifluorescence setup. (bottom) Insets show enlargements   
of the boxed areas. Arrowheads point to endosomal organelles indicating presence (A–C and E) or absence (F) of colocalization between markers.   
(G) Colocalization analysis of CAV1-mCherry endosomal structures with endosomal markers. The fraction of CAV1-mCherry endosomes per cell colocalizing 
with EGFP-Rab5 (n = 68 cells), EGFP-Rab7 (n = 68 cells), and Lamp1-EGFP (n = 43 cells) was determined as detailed in Materials and methods (Fig. S2 A) 
from images acquired from living cells using an epifluorescence setup. Box plots show medians, lower and upper quartiles (line and box), 10th and 90th 
percentiles (whiskers), and outliers (•). Bars: (A–C, E, and F) 10 µm; (D) 1 µm.JCB • VOLUME 191 • NUMBER 3 • 2010   622
When expressed in CV1 cells, a GFP-tagged form of the mu-
tant readily reached the plasma membrane, where it was detect-
able as subresolution spots typical for caveolae (Fig. S3 B). 
Successful caveolae assembly of the mutant was also con-
firmed by sucrose velocity centrifugation of lysates prepared 
from cells expressing GFP- or HA-tagged CAV1-K*R (Fig. S3 C; 
membranes with anti-ubiquitin (FK2) to detect ubiquitin re-
vealed multiple corresponding bands (Fig. 6 A).
To confirm that CAV1 was the ubiquitinated species ob-
served in the pull-down experiments, we engineered a version 
of CAV1 that could no longer be ubiquitinated as a result of 
mutation of all 12 lysines to arginines (CAV1-K*R; Fig. S3 A). 
Figure 5.  CAV1 is exposed to the acidic lumen of LE/LYS. (A) CAV1-mEGFP and CAV1-mCherry colocalized in caveolar spots in the plasma membrane 
(dashed inset, contrast adjusted) but not in many of the intracellular organelles when imaged live. (B) CV1 cells expressing CAV1-mCherry were stained with 
100 nM LysoTracker (green) for 1 h and imaged live to identify acidic organelles. Most acidic organelles were positive for CAV1-mCherry. (C) Colocalization 
between CAV1-mEGFP and CAV1-mCherry in endosomes was restored by treatment of cells with 0.2 µM BafA (12 h), indicating acid quenching of mEGFP 
fluorescence. (A–C) Single confocal sections of live cells. (top) Insets show enlargements of boxed areas. (D and E) Live cell time-lapse imaging of CV1 cells 
coexpressing CAV1-mEGFP and CAV1-mCherry to monitor acid-dependent quenching of CAV1-mEGFP fluorescence during endosomal maturation. (D) An 
endosome initially positive for CAV1-mEGFP and CAV1-mCherry was tracked over 42 min as outlined in E, and fluorescence intensity profiles were plotted 
against time. CAV1-mEGFP fluorescence decayed over time, whereas CAV1-mCherry fluorescence was stable. To rule out photobleaching of mEGFP, the total 
perinuclear mEGFP fluorescence was measured and plotted (E, blue dashed outline; D, intensity profile). Time-lapse series were recorded with epifluorescence 
illumination at 0.2 Hz. (F) Stills of the CAV1-mEGFP and CAV1-mCherry–positive endosome tracked in D (Video 3). Bars: (A–C) 10 µm; (E) 5 µm; (F) 0.5 µm.623 Caveolin degradation • Hayer et al.
conditions to exclude noncovalent association of ubiquitin con-
jugates (Fig. S3 D).
To determine whether the ubiquitinated CAV1 was present 
in EE, CV1 cells coexpressing CAV1-HA and EGFP-Rab5 were 
stained with both anti-CAV1 (N20) and anti-ubiquitin (FK2) anti-
bodies. Confocal microscopy revealed extensive colocalization   
Hayer et al., 2010). When CAV1-K*R-HA was used in the 
pull-down experiment, no ubiquitinated species were observed, 
confirming that CAV1 was indeed ubiquitinated. CAV1 was 
also found to be ubiquitinated when immunoprecipitations 
were performed from lysates of HEK293 cells coexpressing 
CAV1-myc and HA-ubiquitin, both under native and denaturing 
Figure 6.  CAV1 is ubiquitinated. (A) HEK293 cells were 
transfected  with  CAV1-HA  or  CAV1-K*R-HA,  and  CAV1 
was immunoprecipitated using anti-CAV1 (N20) antibody. 
Probing blots with anti-ubiquitin (FK2) antibody revealed 
ubiquitinated  CAV1  species  in  immunoprecipitates  pre-
pared  from  cells  expressing  wild-type  CAV1-HA  but  not 
from cells expressing the lysine-null mutant CAV1-K*R-HA. 
Migration of molecular mass standards is indicated in   
kilodaltons. (B) Pulse-chase analysis showed that turnover of 
CAV1-K*R-HA was slowed down by 47% when compared 
with wild-type CAV1 (CAV1-HA). Error bars indicate mean ±   
SD  from  three  samples  collected  on  two  experimental   
days. (C) Ubiquitin staining accumulated and colocalized 
with overexpressed CAV1-HA in Rab5-positive EE of CV1 
cells. (D–F) Accumulation of ubiquitin in EE was not ob-
served in cells transfected with the lysine-null mutant CAV1-
K*R-HA (D), in untransfected cells (E), or in cells transfected 
with mRFP-Rab5/EGFP-Rab7 (F). Single confocal sections 
of fixed cells are shown. (C–F, bottom) Insets show enlarge-
ments of boxed areas. Bars, 10 µm.JCB • VOLUME 191 • NUMBER 3 • 2010   624
wild-type CAV1-HA, demonstrating that ubiquitination was 
important for CAV1 degradation (Fig. 6 B).
Together, the results showed that CAV1 was ubiquitinated.   
In cells overexpressing CAV1, the ubiquitinated forms accumu-
lated in Rab5-positive EE. Ubiquitination was specifically re-
quired for CAV1 degradation because a mutant of CAV1 that could 
not be ubiquitinated displayed attenuated degradation kinetics.
Ubiquitination and ESCRT components Hrs 
and Tsg101 are required for ILV targeting 
of CAV1
If ubiquitination was required for ILV targeting of CAV1, de-
pletion of free ubiquitin by treating cells with the proteasome 
between CAV1 and ubiquitin in Rab5-positive EE (Fig. 6 C).   
Strikingly, accumulation of anti-ubiquitin signal was observed only 
when cells were transfected with wild-type CAV1 but not with the 
lysine-null mutant CAV1-K*R (Fig. 6 D). Untransfected cells or 
cells transfected with tagged Rab5/Rab7 alone displayed a typical 
homogenous ubiquitin distribution in the cytoplasm and nucleus 
(Fig. 6, E and F). Therefore, ubiquitinated CAV1 was detectable only 
when abundant CAV1 was present in the endolysosomal pathway.
To directly address the relevance of ubiquitination for 
degradation of CAV1, we tested whether the lysine-null mu-
tation affected the degradation kinetics of CAV1. Indeed, when 
CAV1-K*R-HA was tested in pulse-chase experiments, degra-
dation of the mutant was reduced by 47% when compared with 
Figure 7.  CAV1 ubiquitination and ESCRT machinery are needed for ILV targeting. (A) In CV1 cells expressing mEGFP-mCherry (tandem)–tagged CAV1, 
mCherry fluorescence did not overlap with mEGFP fluorescence in many endosomal structures, indicating acid-dependent quenching of mEGFP in LE/LYS 
(Fig. 5 A). (B and C) Treatment of cells with 20 mM NH4Cl (B) or 10 µM MG132 (C) restored mEGFP fluorescence, which is consistent with neutralized 
lumenal pH and defects in ILV targeting, respectively. HeLa cells pretreated for 48 h with control siRNA (D) or siRNAs targeting ESCRT components Hrs and 
Tsg101 (E; double knockdown) were transfected with CAV1-tandem for 12 h and viewed live by confocal microscopy. The presence of yellow endosomes 
upon knockdown of Hrs and Tsg101 showed involvement of ESCRT machinery in ILV targeting of CAV1. (F) Western blot analysis indicated successful 
knockdown of Hrs and Tsg101. (A–E) Single confocal sections of live cells are shown. (bottom) Insets show enlargements of boxed areas. Bars, 10 µm.625 Caveolin degradation • Hayer et al.
in cellular cholesterol using U18666A also dramatically increased 
the level of free, rapidly diffusing CAV1 in the plasma mem-
brane at the expense of caveolae. Cholesterol is required for the 
assembly of caveolae in the Golgi; it binds directly to caveolins 
and serves as an essential component of the lipid raft–like mem-
brane microdomain (Murata et al., 1995).
In addition to elevating the free CAV1 in the plasma mem-
brane, these three conditions caused the accumulation of CAV1 in 
Lamp1-positive endolysosomal vacuoles in the cytoplasm. This 
indicated that excess, unassembled CAV1 was targeted to the deg-
radative branch of the endocytic pathway. Inhibition with NH4Cl 
and BafA confirmed that the degradation occurred in LYS.
Under normal, unperturbed conditions, CAV1 in the plasma 
membrane is localized in caveolae without a detectable free pool.   
It has been shown by immunofluorescence and with live cell imag-
ing that some CAV1 also resides in EE, where it forms defined   
domains (Pol et al., 2000; Pelkmans et al., 2004). The binding of 
cavin-1 to early endosomal CAV1 indicated that CAV1 in the EE 
possessed, at least in part, the mature, assembled conformation.
That indirect immunofluorescence did not show a pres-
ence of endogenous CAV1 in LE or LYS may not only be be-
cause of its slow rate of turnover and its low abundance in these 
organelles but also because of a fixation artifact that makes it 
difficult to demonstrate antigens present in ILV of CV1 cells. 
Although EE were properly fixed using various FA-based fixa-
tives,  the  majority  of  Lamp1-containing  organelles  ruptured 
during fixation and released their contents, including CAV1, 
into the cytoplasm. Therefore, to analyze late endosomal com-
partments, live cell imaging was more reliable than immuno-
fluorescence microscopy but could only be performed with tagged 
forms of CAV1 and endosomal markers. In unperturbed, stable 
cell lines expressing fluorescently tagged CAV1 at relatively 
low levels, no staining was seen in LE/LYS. In contrast, tran-
sient overexpression of fluorescent CAV1 resulted in rapid ac-
cumulation in Rab5-, Rab7-, and Lamp1-positive organelles.
Electron microscopy using immunogold labeling in HepG2 
cells has previously shown that endogenous CAV1 can be found 
in multivesicular bodies (Botos et al., 2008) and that stimulation 
of caveolar endocytosis with albumin increases targeting of 
CAV1 to this compartment, suggesting a correlation between 
caveolar trafficking and lysosomal CAV1 degradation. That deg-
radation of endogenous CAV1 occurs in LYS is also supported by 
the observations that siRNA-mediated knockdown of flotillin-1 
and cavin-1, as well as treatment of cells with PDGF, causes ac-
celerated degradation of CAV1 and that this is sensitive to inhib-
itors of lysosomal degradation (Peterson et al., 2003; Hill et al., 
2008; Vassilieva et al., 2009).
When CAV1 was overexpressed, a clear ubiquitin signal 
was observed in EE. Without CAV1 overexpression or after 
overexpression of the lysine-null mutant of CAV1, there was 
no  such signal. Biochemical analysis confirmed that a large 
fraction of the CAV1 present in the cells was in fact poly- or 
monoubiquitinated and that ubiquitination was important for 
accelerated CAV1 degradation. Likewise, depletion of free ubiq-
uitin by MG132 and siRNA knockdown of Hrs and Tsg101 
showed that both ubiquitin and the ESCRT machinery were re-
quired to target CAV1 to ILV. Before closure of ILV, the cargo 
inhibitor MG132 was expected to prevent ILV targeting and ex-
posure of CAV1 to the acidic lumen of endosomes. To address 
this possibility, we modified our dual-tagging strategy where 
CAV1-mCherry but not CAV1-mEGFP was visible in acidic 
LE/LYS  by  constructing  CAV1  tagged  with  mEGFP  and 
mCherry at its C terminus (tandem tag, CAV1-tandem). Al-
though not affecting the subcellular localization of CAV1, the 
tandem tag provided higher fluorescence intensity and a more 
constant ratio of GFP/mCherry signal than coexpressing indi-
vidually tagged CAV1. The presence of red endosomes was 
used as readout for successful targeting of CAV1-tandem to the 
acidic lumen of endosomes.
As expected, many endosomes were red in control cells, 
whereas endosomes were both red and green in cells treated 
with NH4Cl (Fig. 7, A and B). Strikingly, in the presence of 10 µM 
MG132 (12 h), most endosomes remained both red and green, 
which is consistent with a ubiquitin- or proteasome-dependent 
inclusion of CAV1 in ILV during late endosomal maturation   
(Fig. 7 C) but also with the reduced rate of CAV1 degradation 
observed in the presence of MG132 (Fig. 3 B).
A similar strategy was followed to test the involvement of the 
ESCRT machinery in ILV targeting of CAV1. HeLa cells pretreated 
with siRNAs (48 h) targeting the ESCRT components Hrs and 
Tsg101 or control siRNA were transfected with CAV1-tandem, 
and endosomal CAV1 was visualized by confocal microscopy. Ini-
tial experiments, in which Hrs or Tsg101 were individually knocked 
down, did not produce a strong phenotype (unpublished data). 
However, upon double knockdown of both Hrs and Tsg101, severe 
defects in ILV targeting of CAV1-tandem were observed with 
CAV1-tandem–positive endosomes remaining both red and green 
(Fig. 7, D–F). Together, not only was CAV1 ubiquitinated and 
ubiquitination required for its degradation, but ubiquitin served as 
a sorting signal for ILV targeting of CAV1, a process that required 
ESCRT components Hrs and Tsg101.
Discussion
Caveolae in the plasma membrane are stable structures, and CAV1 
is, correspondingly, a remarkably long-lived protein. However, 
when caveolae assembly was perturbed, we found that the frac-
tion of unassembled CAV1 in cells was elevated, and the turnover 
dramatically accelerated. The protein was targeted to endosomes, 
ubiquitinated, sequestered into ILV by the ESCRT machinery, 
and degraded in LYS (Fig. 8). The results allowed us to explain 
observations regarding the life cycle of CAV1 and about the na-
ture of caveolin-rich vacuoles called caveosomes, previously de-
scribed after CAV1 overexpression by our group.
One of the perturbations used to increase the turnover of 
CAV1 was, indeed, its overexpression. Apparently, overabun-
dance of this caveolar component resulted in saturation of caveo-
lae assembly in the Golgi complex, generation of a rapidly 
diffusing pool of free CAV1 in the plasma membrane, and a 
drop in t1/2 from >36 h for endogenous to 13.6 h for over-
expressed CAV1. Silencing of cavin-1 resulted in a similar effect 
with an almost complete loss of 70S caveolar scaffolds in the 
cell, accumulation of 8S caveolin intermediates, and again, a 
diffuse plasma membrane distribution of CAV1. The reduction JCB • VOLUME 191 • NUMBER 3 • 2010   626
in the lumen of the vacuoles and not in the limiting membrane, 
whereas in EE, its localization still coincided with Rab5 in the 
limiting membrane.
The quenching of CAV1-mEGFP fluorescence in LE/LYS 
observed in live cells showed that CAV1 in the ILV became   
proteins to be degraded are usually deubiquitinated. The selec-
tive targeting of activated EGF receptor and other membrane 
proteins for destruction in LYS occurs in this way (Raiborg and 
Stenmark, 2009). When viewed in live cells, the CAV1 present 
in Rab7- and Lamp1-positive LE/LYS was in fact mainly localized 
Figure 8.  Model of caveolae disassembly and degradation of CAV1. Disassembly involves the release of cavin-1 from an intact caveola followed by dis-
sociation of the destabilized 70S caveolar scaffold into 8S caveolar complexes. This may occur in EE after caveolar endocytosis or in the plasma membrane 
(PM), from where disassembled CAV1 is delivered to EE as endocytic cargo. Unassembled CAV1 may also arise when assembly of caveolar scaffolds in 
the Golgi is compromised and CAV1 arrives in the plasma membrane in the form of 8S complexes. In endosomes, the ubiquitinated 8S caveolar complexes 
are recognized by the ESCRT machinery and targeted to ILV facing the lumen. Upon lysis of ILV in LYS, CAV1 is exposed to the acidic vacuolar pH and 
degraded by proteolytic cleavage.627 Caveolin degradation • Hayer et al.
these complexes into EE. (b) The assembly of caveolar scaffolds 
in the Golgi complex may be compromised, e.g., because of over-
expression of CAV1 or lack of cholesterol, resulting in the arrival 
of unassembled, freely diffusing 8S complexes to the plasma 
membrane followed by endocytosis and delivery to EE. (c) In the 
absence of cavin-1, the caveolar scaffolds may still be assembled 
in the Golgi complex, but being unstable, they dissociate into 8S 
complexes soon after insertion into the plasma membrane (Hayer 
et al., 2010). (d) Dissociation of caveolar scaffolds may also occur 
in EE after endocytosis of intact caveolar domains in the form of 
caveolar vesicles and their fusion with EE. In this case, the loss   
of cavin-1 may allow dissociation of the endosomal caveolar scaf-
folds. The degradation of caveolae is a stepwise process involving 
many components. It remains to be determined how the dis-
assembly of the highly stable, long-lived caveolar domain is regu-
lated by ubiquitination, the cavins, and other cellular factors.
Materials and methods
Cell culture and transfections
CV1 and HeLa cells (American Type Culture Collection) were grown in 
DME (Invitrogen) supplemented with 10% FCS and 5% Glutamax (Invitro-
gen). HeLa cells stably expressing CAV1-mRFP (Tagawa et al., 2005) were 
maintained as HeLa cells but in the presence of 0.5 mg/ml G418. HEK293 
cells were grown as CV1 but in the presence of penicillin/streptomycin. 
CV1 cells stably expressing CAV1-mEGFP (CV1-CAV1-mEGFP) were gener-
ated using the parental cell line CV1–Flp-In (Invitrogen) and the plasmid 
CAV1-mEGFP/FRT/TO, following the manufacturer’s protocol for Flp-In re-
combination (Invitrogen). In a similar way, CV1-GFP-GPI cells were gener-
ated using the plasmid GFP-GPI/FRT/TO. Both recombinant cell lines were 
grown as CV1 cells but in the presence of 150 µg/ml hygromycin. CV1 
cells were transfected with cDNA by electroporation according to the manu-
facturer’s recommendation (Nucleofector kit V; program A24; Lonza), and 
HEK293 cells were transfected by the calcium phosphate method.
Plasmid constructs
CAV1-mEGFP, CAV1-mCherry, CAV1-HA, and cavin-1–mEGFP have been de-
scribed previously (Hayer et al., 2010). To generate CAV1-mEGFP/FRT/TO, 
the coding sequence for CAV1-mEGFP was excised from the plasmid CAV1-
mEGFP  as  HindIII–NotI  fragment  and  ligated  into  appropriately  digested 
pcDNA5/FRT/TO (Invitrogen). GFP-GPI/FRT/TO was generated by subclon-
ing GFP-GPI from EGFP-GL-GPI (Keller et al., 2001) into pcDNA5/FRT/TO   
(Invitrogen) as HindIII–NotI fragment. CAV1-tandem was constructed first 
by PCR amplification of mEGFP flanked by BamHI and AgeI sites using 
primers (sense) 5-ATGGATCCAGTGAGCAAGGGCGAGGAGC-3 and 
(antisense) 5-ATACCGGTTTGTACAGCTCGTCCATGCCG-3 and liga-
tion into BamHI–AgeI-digested CAV1-mCherry (pcDNA5/FRT/TO back-
bone), yielding CAV1-mEGFP-mCherry (CAV1-tandem). The cDNA encoding 
the CAV1 mutant with all 12 lysines mutated into arginines (CAV1-K*R) was 
synthesized by GENEART AG as a sequence flanked by HindIII–BamHI sites 
and a C-terminal HA tag followed by a NotI site. Ligation of the HindIII–
NotI- or HindIII–BamHI-digested fragment into appropriately digested 
pmEGFP-N1 backbone fragments yielded CAV1-K*R-HA or CAV1-K*R-mEGFP, 
respectively. Cavin-1–mCherry was generated based on cavin-1–mEGFP 
by swapping mEGFP against mCherry as AgeI–BsrGI fragment. EGFP-Rab5 
was provided by M. Zerial (Max Planck Institute of Molecular Cell Biology 
and Genetics, Dresden, Germany), EGFP-Rab7 and Lamp1-EGFP were 
provided by J. Gruenberg (University of Geneva, Geneva, Switzerland), 
HA-ubiquitin was provided by P. De Camilli (Yale University School of Medi-
cine, New Haven, CT), and CAV1-myc was provided by J. Pessin (Albert 
Einstein College of Medicine, New York, NY). mRFP-Rab5 has been described 
previously (Vonderheit and Helenius, 2005). Plasmid constructs generated in 
this study will be made available through Addgene after publication.
Antibodies and other reagents
Rabbit pAb anti-CAV1 (N20; sc-894), mouse mAb anti-LAMP1 (sc-20011), 
and mouse mAb anti–c-myc (9E10; sc-40) were obtained from Santa Cruz 
Biotechnology, Inc., rabbit pAb anti-PTRF (polymerase I and transcript re-
lease  factor;  cavin-1)  from  Abcam  (ab48824),  rabbit  pAb  anti-giantin 
(PRB-114C) and mAb anti-HA from Covance (MMS-101P), mAb anti-Hrs 
exposed to low pH. Given the membrane topology of CAV1 and 
the location of the GFP at the C terminus, this shift implied that 
the protection of the GFP by the ILV membrane was lost and the 
GFP exposed to a pH <6.0. After expressing CAV1 tagged with 
mEGFP and mCherry separately or in tandem, we could follow 
the maturation of individual endosomes in live cells by observ-
ing the shift from yellow to red fluorescence. Such a dual-tag 
strategy may be of general use in studies of ILV formation, 
acidification, and LE/LYS maturation in living cells.
Earlier experiments from our laboratory indicated that during 
entry into CAV1-EGFP–expressing CV1 cells, incoming SV40   
in transit from the plasma membrane to the ER enters CAV1-rich 
intracellular organelles (Pelkmans et al., 2001). These organelles 
were called caveosomes because they seemed to differ from nor-
mal endosomes. They were characterized by the abundant pres-
ence of CAV1-EGFP, they did not contain endosomal markers, and 
their lumenal pH was neutral (Pelkmans et al., 2001).
Subsequently, we found that incoming viruses do in fact pass 
through EE and LE on their way to the ER, where penetration   
occurs (unpublished data). In view of the new SV40 data and the 
results presented in this study, we no longer consider caveosomes 
independent organelles. Under normal conditions, we find that   
endogenous CAV1 can be observed in EE but, typically, not in LE/
LYS. However, when highly overexpressed, as it was in our studies 
describing caveosomes, CAV1-EGFP and other forms of CAV1   
accumulated in late organelles of the endocytic pathway. These 
contain ILV and LE/LYS markers such as Rab7 and Lamp1. These 
are markers that were not tested in the original caveosome studies.
There may be several reasons why the original studies de-
scribing caveosomes (Pelkmans et al., 2001, 2004) came to the 
conclusion that their lumenal pH is neutral. The pH of CAV1-
containing organelles was not determined directly, but inferred 
from bulk pH measurements using SV40 as a probe, from cells in 
suspension. Moreover, time course analysis of SV40 entry and 
drug wash-in experiments now suggest that the time point at 
which the pH was measured, using the fluorescent virus as the pH 
probe, was not well chosen because a large fraction of virus may 
have already reached the ER, i.e., a neutral environment, by the 
time the measurements were undertaken (unpublished data).
The electron micrographic sections showing structures with 
many caveolar domains most likely represent structures still con-
nected to the plasma membrane (Parton and Simons, 2007; Kiss 
and Botos, 2009). We emphasize that caveosomes, according to 
our present data, are most likely modified LE/LYS and thus part 
of the classical endocytic pathway. We suggest that the term   
caveosome no longer be used.
In the light of our findings, we propose that the degradation 
of CAV1 occurs in LE/LYS after inclusion of CAV1 into ILV by 
the ESCRT complexes localized in EE (Fig. 8). Degradation   
only occurs if CAV1 is present in 8S complexes because the intact 
caveolar scaffolds are too big to be included in ILV. To be recog-
nized by the ESCRT machinery and sequestered after deubiqui-
tination in ILV, the 8S complexes must, moreover, be present in 
the EE and be ubiquitinated. The 8S complexes can be formed in 
the following different ways: (a) caveolar scaffolds in the plasma 
membrane may be destabilized, e.g., by the loss of cavin-1, fol-
lowed by dissociation into 8S complexes and the endocytosis of JCB • VOLUME 191 • NUMBER 3 • 2010   628
FRAP
For FRAP experiments, either CV1-CAV1-mEGFP cells untreated or treated 
with 5 µg/ml U18666A (16 h) or CV1-GFP-GPI cells were used. Coverslips 
with cells were transferred to a custom-built metal microscope coverslip cham-
ber in CO2-independent medium (Invitrogen) supplemented with 10% FCS. 
FRAP analyses were performed at 37°C on an inverted confocal microscope 
system (LSM 510 Meta) equipped with a temperature-controlled stage and a 
63× 1.4 NA objective. A defined region of interest (4 × 4 µm) was bleached 
using the 488-nm line of a 30-mW Ar laser at high laser intensity (100% 
power, 100% transmission, and 30 iterations), and fluorescence recovery 
was recorded by scanning at low laser intensity (100% power and 10% 
transmission). Images were acquired as 12-bit LSM files at 512 × 512 pixels/
frame and 0.14 µm/pixel lateral resolution. Image series with little or no ap-
parent motion of cells were imported into ImageJ and automatically aligned 
using the TurboReg plug-in (http://bigwww.epfl.ch/thevenaz/turboreg/; 
Thévenaz et al., 1998). The mean fluorescence intensity of the region of inter-
est was determined after background subtraction and normalization as de-
scribed previously (Phair and Misteli, 2000).
Live cell fluorescence imaging
CV1 cells expressing fluorescently tagged constructs and seeded on 18-mm 
coverslips were transferred to a custom-built metal microscope coverslip cham-
ber in CO2-independent medium (Invitrogen) supplemented with 10% FCS. TIR 
and epifluorescence time-lapse imaging were performed on a microscope 
(IX71; Olympus) equipped with a camera (IMAGO QE; TILL Photonics), dual 
condenser (TIR/EPI; TILL Photonics), ArKr laser (Spectra Physics), acousto-optic 
tunable  filters  (Optoelectronics,  Inc.),  a  monochromatic  light  source  poly-
chrome IV (TILL Photonics), a dual-view beam splitter (Optical Insights) in the 
emission light path, a 60× 1.45 NA objective, and a temperature-controlled 
incubation chamber, and using MetaMorph software (MDS Analytical Tech-
nologies). For TIR illumination of CAV1-mEGFP, the 488-nm laser line was 
used, and the depth of the evanescent field was adjusted such that both ventral 
cell surface and parts of the Golgi complex were illuminated. For epiillumina-
tion, the monochromator was used at 488 and 568 nm with a beam splitter in 
the detection light path to avoid cross talk between mEGFP and mCherry sig-
nals. Confocal live cell imaging was performed on a system (LSM 510 Meta) 
equipped with a 100× 1.4 NA objective and a temperature-controlled stage.
Colocalization analysis
Images were acquired from living cells expressing CAV1-mCherry and 
EGFP-tagged endosomal markers using the aforementioned system (IX71; 
Olympus) using a monochromatic light source (EPI illumination), a 60× 
1.45 NA objective, and a filter wheel in the emission light path. A custom-
written analysis routine implemented in MATLAB (MathWorks) was used to 
detect endosomal structures and determine overlap (Gupta et al., 2009). 
About 6 × 10
4 endosomes were analyzed in total from n = 68 cells for 
CAV1-mCherry/Rab5-EGFP, n = 68 cells for CAV1-mCherry/Rab7-EGFP, 
and n = 43 cells for CAV1-mCherry/Lamp1-EGFP.
Online supplemental material
Fig. S1 shows expression levels of CAV1-mRFP and CAV1-mEGFP stably trans-
fected in HeLa and CV1 cells, respectively, relative to endogenous CAV1. Both 
fusion proteins were efficiently incorporated into 8S/70S-equivalent caveolar 
complexes. Fig. S1 also shows that accumulation of CAV1 in endosomal or-
ganelles upon overexpression could not be reversed by co-overexpression of 
cavin-1. Fig. S2 illustrates the automated colocalization analysis method used 
and shows how CAV1-mCherry in the lumen of LE/LYS but not the LE/LYS 
membrane marker Lamp1-EGFP was lost during FA fixation. Fig. S3 describes 
and characterizes the lysine-null mutant of CAV1 (CAV1-K*R) by showing 
that the mutant was efficiently incorporated into 8S/70S-equivalent caveolar   
complexes  when  expressed  in  CV1  cells  and  that  it  reached  the  plasma 
membrane, where it localized to caveolar spots. Fig. S3 also shows immuno-
precipitations of CAV1 performed under denaturing conditions, confirming that 
CAV1 is ubiquitinated. Video 1 shows that, in cells pretreated with U18666A,   
newly synthesized CAV1-mEGFP reached the plasma membrane in un-
assembled form. Video 2 illustrates that in LE/LYS, lumenal CAV1-mCherry 
was lost short after addition of FA fixative, whereas Lamp1-EGFP in the limiting 
membranes was properly fixed. In Video 3, our dual-tag strategy was used 
to follow targeting of CAV1-tandem to the acidic lumen of individual matur-
ing endosomes. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201003086/DC1.
We thank Gautam Dey for providing colocalization analysis scripts and Pietro 
De Camilli, Jean Gruenberg, Jeffrey Pessin, Kai Simons, and Marino Zerial for 
generous gifts of plasmids. We are grateful to Fabian Herzog for preparing the 
cell line CV1-GFP-GPI. We also thank Jason Mercer for comments on the man-
uscript and the Helenius laboratory for support and helpful advice.
from  Sigma-Aldrich  (6D11;  WH0009146M1),  mAb  anti-Tsg101  from 
Axxora (4A10; NB200-112), mouse mAb anti–-actin from Sigma-Aldrich 
(AC-15; A1978), and mouse mAb anti-ubiquitin from Enzo Life Sciences, 
Inc. (FK2; BML-PW8810-0500). Rabbit pAb anti-calnexin was produced in 
house. Alexa Fluor–conjugated secondary antibodies for immunofluores-
cence and LysoTracker green were obtained from Invitrogen.
Velocity gradient centrifugation
Sucrose velocity gradient centrifugation was performed as described previ-
ously (Hayer et al., 2010). In brief, cells were solubilized at 25°C in 0.5% 
Triton X-100 (TX100) in TNE (20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 
and 5 mM EDTA) supplemented with Complete protease inhibitor cocktail 
(Roche). Postnuclear supernatants were loaded onto 10–40% linear su-
crose  gradients  prepared  in  0.5%  TX100/TNE  and  spun  in  a  rotor 
(SW55Ti; Beckman Coulter) at 50,000 rpm (237,020 g) and 4°C for   
255 min. Gradient fractions were analyzed by SDS-PAGE/Western blotting.
RNAi
The siRNA oligomers targeting PTRF/cavin-1 (SI04178496), Hrs (SI00288239),   
and Tsg101 (SI02655184) were purchased from QIAGEN and transfected 
into HeLa-CAV1-mRFP or HeLa cells at 10 nM using Lipofectamine RNAiMAX 
(Invitrogen) according to the manufacturer’s recommendations and as previ-
ously described (Hayer et al., 2010). Nontargeting siRNA (AllStarsNeg;   
QIAGEN) was used as control siRNA. Cells were analyzed 60–72 h after 
transfection as indicated.
Metabolic labeling, immunoprecipitations, and autoradiography
Per sample, 3 × 10
5 cells expressing CAV1 variants for 6 h after electro-
poration or untransfected CV1 cells were first starved for 45 min in Cys/
Met-free DME (Sigma-Aldrich) and pulse labeled for 1 h or 4 h, respec-
tively, using 0.2 mCi/ml [
35S]Cys/Met Promix (NEG772007; PerkinElmer) 
in  otherwise  Cys/Met-deficient  DMEM.  Cells  were  washed  with  and 
chased in full medium (DMEM, 10% FCS, and 1% Glutamax) supplemented 
with 5 mM Cys, 5 mM Met, 50 mM Hepes, pH 7.4, and 1× penicillin/ 
streptomycin. For drug treatments, CV1 cells expressing CAV1-HA were 
pulse labeled for 1 h and chased for 1 h before addition of drugs   
(10 mM leupeptin, 0.2 µM BafA in DMSO, 20 mM NH4Cl, 5 µg/ml 
U18666A, and 10 µM MG132 in DMSO) to ensure that drugs did not inter-
fere with delivery of labeled CAV1 to the plasma membrane. Cells chased for 
the indicated times (15 h total for drug treatments and CAV1-K*R-HA) were 
solubilized in 500 µl RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl,   
1 mM EDTA, 1% TX100, 1% Na-deoxycholate, and 0.1% SDS) supplemented 
with Complete protease inhibitor cocktail (Roche) at 4°C. For immuno-
precipitations, lysates were incubated 2 h or overnight at 4°C with 2 µg anti-
CAV1  (N20)  antibody,  and  complexes  were  recovered  with  protein 
G–Sepharose  (GE  Healthcare).  Immunoprecipitates  were  washed  four 
times using RIPA buffer, eluted by boiling in SDS sample buffer, and sepa-
rated by SDS-PAGE. Labeled protein was visualized using a phospho-
imager (STORM; MDS Analytical Technologies), and bands were quantified 
with ImageJ (National Institutes of Health).
Native and denaturing immunoprecipitations for detection of 
ubiquitinated CAV1
HEK293 cells were transfected with CAV1-HA, CAV1-K*R-HA, empty vector, 
or cotransfected with CAV1-myc and HA-ubiquitin by the Ca3(PO4)2 method. 
24 h later, cells were scraped into PBS, pelleted, and solubilized in 250 µl 
immunoprecipitation buffer (150 mM KCl, 50 mM Tris, pH 7.4, 5 mM 
MgCl2,  1%  TX100,  5%  glycerol,  and  2  mM  -mercaptoethanol  supple-
mented with Complete protease inhibitor cocktail). For denaturing immuno-
precipitations, extracts prepared in 100 µl of immunoprecipitation buffer 
were first boiled in the presence of 1% SDS for 5 min and then diluted 1:10 
using immunoprecipitation buffer containing 1 mg/ml BSA to yield 0.1% 
SDS final concentration. Lysates were spun down at 15,800 g for 10 min at 
4°C, supernatants were incubated with 2 µg anti-CAV1 (N20) for 1.5 h at 
4°C, and immunocomplexes were precipitated using protein G–Sepharose. 
500 µg protein in 250 µl or 1 ml final volume was used for native or denatur-
ing immunoprecipitates, respectively. Immunoprecipitates were resolved by 
SDS-PAGE and analyzed by Western blotting.
Immunofluorescence imaging
Cells grown on coverslips were fixed using 4% FA in PBS. Cells were per-
meabilized using 0.05% saponin and 1% BSA in PBS and incubated with 
the  appropriate  primary  (1:500)  and  secondary  (1:1,000)  antibodies, 
and coverslips were mounted on slides using Immumount (Thermo Fisher 
Scientific). Imaging was performed on an inverted confocal microscope 
system (LSM 510 Meta; Carl Zeiss, Inc.) using a 100× 1.4 NA objective.629 Caveolin degradation • Hayer et al.
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